Literature DB >> 1684155

RU 41,656 does not reverse the scopolamine-induced cognitive deficit in healthy volunteers.

A Patat1, M J Klein, A Surjus, M Hucher, J Granier.   

Abstract

The potential antagonism of a single oral dose of RU 41,656 10 mg on the memory and attention disturbances induced by scopolamine 0.6 mg s.c. have been investigated in a 3 period, placebo controlled, double blind, cross over study in 12 healthy, young volunteers. The effects of the compounds were evaluated by objective tests (Buschke selective reminding test, CFF, simple reaction time, tapping, arithmetical calculation) and subjective measurements (visual analogue scale, side effects questionnaire). Measurements were taken before treatment and 2, 4 and 7 h after RU 41,656. Scopolamine caused anterograde amnesia and sedative effects as which were not counteracted by RU 41,656.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1684155     DOI： 10.1007/BF00315434

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


  40 in total

1.  Scopolamine and the control of attention in humans.

Authors:  M P Dunne; L R Hartley
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

2.  Cholinergic modulation of human P3 event-related potentials.

Authors:  E J Hammond; K J Meador; R Aung-Din; B J Wilder
Journal:  Neurology       Date:  1987-02       Impact factor: 9.910

3.  Evaluating storage, retention, and retrieval in disordered memory and learning.

Authors:  H Buschke; P A Fuld
Journal:  Neurology       Date:  1974-11       Impact factor: 9.910

4.  Concreteness, imagery, and meaningfulness values for 925 nouns.

Authors:  A Paivio; J C Yuille; S A Madigan
Journal:  J Exp Psychol       Date:  1968-01

5.  The separate and combined effects of scopolamine and nicotine on human information processing.

Authors:  K Wesnes; A Revell
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

Review 6.  Pharmacologic modelling of Alzheimer's disease.

Authors:  T Sunderland; P N Tariot; H Weingartner; D L Murphy; P A Newhouse; E A Mueller; R M Cohen
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1986       Impact factor: 5.067

7.  Patterns of memory failure after scopolamine treatment: implications for cholinergic hypotheses of dementia.

Authors:  W W Beatty; N Butters; D S Janowsky
Journal:  Behav Neural Biol       Date:  1986-03

8.  Effects of scopolamine (0.25-0.75 mg i.m.) on the quantitative EEG and the neuropsychological status of healthy volunteers.

Authors:  W G Sannita; L Maggi; G Rosadini
Journal:  Neuropsychobiology       Date:  1987       Impact factor: 2.328

9.  Effects of oral scopolamine on human stimulus evaluation.

Authors:  E Callaway; R Halliday; H Naylor; G Schechter
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

10.  Memory and cognitive function in man: does the cholinergic system have a specific role?

Authors:  D A Drachman
Journal:  Neurology       Date:  1977-08       Impact factor: 9.910
View more
  5 in total

1.  Theory of Visual Attention (TVA) applied to mice in the 5-choice serial reaction time task.

Authors:  C M Fitzpatrick; M Caballero-Puntiverio; U Gether; T Habekost; C Bundesen; S Vangkilde; D P D Woldbye; J T Andreasen; A Petersen
Journal:  Psychopharmacology (Berl)       Date:  2017-01-09       Impact factor: 4.530

Review 2.  Cognition enhancers in age-related cognitive decline.

Authors:  W J Riedel; J Jolles
Journal:  Drugs Aging       Date:  1996-04       Impact factor: 3.923

3.  Effects of dimethylaminoethanol pyroglutamate (DMAE p-Glu) against memory deficits induced by scopolamine: evidence from preclinical and clinical studies.

Authors:  Olivier Blin; Christine Audebert; Séverine Pitel; Arthur Kaladjian; Catherine Casse-Perrot; Mohammed Zaim; Joelle Micallef; Jacky Tisne-Versailles; Pierre Sokoloff; Philippe Chopin; Marc Marien
Journal:  Psychopharmacology (Berl)       Date:  2009-09-16       Impact factor: 4.530

4.  Pharmacological models in Alzheimer's disease research.

Authors:  C Gilles; S Ertlé
Journal:  Dialogues Clin Neurosci       Date:  2000-09       Impact factor: 5.986

5.  Human models as tools in the development of psychotropic drugs.

Authors:  Christian Gilles; Thérèse Schunck; Gilles Erb; Izzie Jacques Namer; Yann Hodé; Jean-François Nedelec; Peter Boeijinga; Remy Luthringer; Jean-Paul Mâcher
Journal:  Dialogues Clin Neurosci       Date:  2002-12       Impact factor: 5.986
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.